FDA approves ODACTRA® for the treatment of house dust mite allergy in young children

ALK ( ALKB:DC / OMX: ALK B ) today announced that the US Food and Drug Administration (FDA) has approved ALK's ODACTRA ®tablet for use in young children with house dust mite (HDM) allergy. ODACTRA ®is now indicated to treat HDM-induced allergic rhinitis, with or without conjunctivitis, in children aged five through 11, in addition to patients aged 12 through 65.  ODACTRA ®is an allergy immunotherapy (AIT) tablet which dissolves under the tongue and helps patients reduce their allergy...

Hørsholm, 27/02/2025 (informazione.news - comunicati stampa - economia)

ALK ( ) today announced that the US Food and Drug Administration (FDA) has approved ALK's ODACTRA tablet for use in young children with house dust mite (HDM) allergy. ODACTRA is now indicated to treat HDM-induced allergic rhinitis, with or without conjunctivitis, in children aged five through 11, in addition to patients aged 12 through 65.  

ODACTRA is an allergy immunotherapy (AIT) tablet which dissolves under the tongue and helps patients reduce their allergy symptoms and their reliance on symptomatic medication.

The FDA approval is an important step in ALK's efforts to make all its respiratory tablets available for all age groups – children, adolescents, and adults - in all relevant markets.

ALK's Executive Vice President of R&D, Henriette Mersebach (MD), says: “ .”

The data that formed the basis for the approval includes results from the largest-ever paediatric AIT Phase 3 clinical trial, MT-12, which involved 1,460 children in North America and Europe. The trial demonstrated efficacy and safety of the treatment in children, and the results were recently published in the reputable scientific journal, The Lancet Regional Health – Europe.

Globally, it is estimated that more than ten million children, aged five to 11, have uncontrolled respiratory allergies and the number is growing. House dust mites are a common cause of allergy and closely linked to asthma.

ALK's house dust mite allergy tablet is marketed as ODACTRA in USA, as ACARIZAX in Europe and several international markets, as MITICURE™ in Japan, and as Sensimune™ in India. Until now, the tablet has been approved for use in young children in Europe and in Japan. A corresponding regulatory review is currently ongoing in Canada.

Furthermore, a separate regulatory review of ALK's tree tablet ITULAZAX also for use in children is currently ongoing in Europe and Canada. These reviews are expected to complete in 2025, after which all ALK's tablets will be approved for children, adolescents, and adults in relevant markets.

The approval is not expected to affect ALK's financial outlook for 2025.

Investor Relations : Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

: Maiken Riise Andersen, tel. +45 5054 1434

Attachment